Phosphorylation of BAD, a pro-apoptotic member of the Bcl-2 protein family, on either Ser112 or Ser136 is thought to be necessary and sufficient for growth factors to promote cell survival. Here we report that Ser155, a site phosphorylated by protein kinase A (PKA), also contributes to cell survival. Ser112 is thought to be the critical PKA target, but we found that BAD fusion proteins containing Ala at Ser112 (S112A) or Ser136 (S136A) or at both positions (S112/136A) were still heavily phosphorylated by PKA in an in vitro kinase assay. BAD became insensitive to phosphorylation by PKA only when both Ser112 and Ser136, or all three serines (S112/136/155) were mutated to alanine. In HEK293 cells, BAD fusion proteins mutated at Ser155 were refractory to phosphorylation induced by elevation of cyclic AMP (cAMP) levels. Phosphorylation of the S112/136A mutant was > > 90% inhibited by H89, a PKA inhibitor. The S155A mutant induced more apoptosis than the wildtype protein in serum-maintained CHO-K1 cells, and apoptosis induced by the S112/136A mutant was potentiated by serum withdrawal. These data suggest that Ser155 is a major site of phosphorylation by PKA and serum-induced kinases. Like Ser112 and Ser136, phosphorylation of Ser155 contributes to the cancellation of the pro-apoptotic function of BAD. 
Results and discussion
Fusion proteins between glutathione-S-transferase and BAD (GST-BAD) carrying the S112A or S136A mutations, singly or in combination (S112/136A), were significantly phosphorylated by PKA (Figure 1a ). This effect was evident for a range of PKA concentrations (0.5 and 0.1 units per reaction), ruling out the possibility that this was an effect at a specific enzyme-substrate ratio. The effect of PKA was abolished by the inclusion of the inhibitor of PKA (PKI, 5 µM) in the in vitro kinase reaction, indicating a specific requirement for PKA (Figure 1b ). These observations suggested that there was an, as yet, unidentified site of PKA-dependent phosphorylation in BAD. Our examination of the protein sequence of murine BAD revealed that Ser155 is nested in a potential PKA phosphorylation site (LRRMS SDE in the single-letter amino-acid code). To investigate whether this site was responsible for the PKA-induced phosphorylation observed in the S112/136A mutant, we generated GST-BAD fusion Ser155 is the preferred site of phosphorylation by PKA. Bacterially expressed GST-BAD fusion proteins eluted from glutathionesepharose beads were used as substrates in an in vitro kinase reaction using either the purified catalytic subunit of PKA or constitutively active PKB immunoprecipitated from PKB-expressing HeLa cells [20] . Kinase reactions were conducted at 35°C for 30 min in the presence of a reaction mix containing [γ-32 P]ATP. The mixes were fractionated by SDS-PAGE and the 32 P-labelled GST-BAD proteins detected by phosphorimaging. (a) PKA (1 unit per reaction) induces phosphorylation of GST-BAD proteins containing the S112A and/or S136A mutations but not proteins bearing the S155A mutation. Protein expression was confirmed by western blotting with a polyclonal anti-BAD antibody (H168, Santa Cruz). (b) Phosphorylation of wildtype (WT) or S112/136A (DM) forms of GST-BAD by PKA is independent of PKA concentration (in the range 1-0.1 units) and is completely abolished by inclusion of PKI. proteins bearing the S155A mutation. Confirming our prediction, PKA failed to phosphorylate the S112/136/155A mutant protein, even when PKA was added in excess. Moreover, the S112/155A and S136/155A mutants were largely refractory to PKA-induced phosphorylation, suggesting that Ser155 is the preferred site of phosphorylation by PKA (Figure 1a) . We also confirmed reports that Ser136 is the major site of phosphorylation by active protein kinase B (PKB) [1] [2] [3] , as none of our S136A mutants were phosphorylatable in vitro by constitutively active PKB (immunoprecipitated from HeLa cells overexpressing PKB). Mutation of Ser112 or Ser155 had no effect on PKB-mediated phosphorylation (Figure 1c) . Thus, PKA and PKB exhibit distinct preferences for Ser155 and Ser136, respectively, of BAD.
To determine whether activation of PKA can induce phosphorylation of BAD at Ser155 in cells, we expressed fusion proteins between various BAD mutants and the enhanced green fluorescent protein (BAD-GFP) in HEK293 cells. Following expression of the proteins (confirmed by probing western blots with an anti-BAD antibody; Figure 2a , top panel), the cells were metabolically labelled with 32 Porthophosphate and treated with the cell-permeable cAMP analogue 8-(4-chlorophenylthio)adenosine 3′,5′-cyclic monophosphate (CPTcAMP). BAD-GFP proteins were then immunoprecipitated using anti-GFP antibody and resolved by SDS-PAGE. CPTcAMP triggered the phosphorylation of wild-type BAD and the S112/136A mutant, but not the S155A or S112/136/155A mutants ( Figure 2a ). To further establish that PKA was responsible for the observed phosphorylations, we examined the pattern of phosphorylation after addition of the adenylyl cyclase agonist forskolin (in the presence of the phosphodiesterase inhibitor IBMX) and added H89, the selective inhibitor of PKA, to test whether phosphorylation could be abolished. Figure 2b shows that treatment of HEK293 cells with 50 µM forskolin and 0.5 mM IBMX induced phosphorylation of wild-type BAD and the S112/136A mutant but not the S112/136/155A mutant. Moreover, preincubation of cells with H89 (60 minutes, 30 µM) followed by treatment with either CPTcAMP or forskolin and IBMX resulted in a significant reduction (> 90%) in the phosphorylation of the S112/136A mutant ( Figure 2b ). Thus, in vivo activation of PKA through elevation of intracellular cAMP levels induces phosphorylation of BAD at Ser155.
To assess the functional importance of BAD phosphorylation on Ser155, we transfected CHO-K1 cells with plasmids encoding wild-type BAD, and the S112/136A, S112/136/155A and S155A mutants, and measured the extent of apoptosis (scored by nuclear morphology and confirmed by polyADP ribose polymerase (PARP) cleavage). That mutation of these sites had no effect on the expression of the respective protein was confirmed by western blotting of lysates derived from transfected CHO-K1 cells and probing with a monoclonal anti-BAD antibody (Figure 3a) . Figure 3b shows that, whereas the expression of GFP alone did not promote apoptosis when the cultures were maintained in serum-containing medium, the absence of Ser155 was sufficient to exacerbate the pro-apoptotic function of wild-type BAD. The amount of apoptosis induced by the S112/136/155A mutant was invariably greater than that induced by either the S155A or S112/136A mutants. In the absence of serum, the level Elevation of intracellular cAMP levels in HEK293 cells causes phosphorylation of wild-type BAD and the S112/136A mutant but not the S112/136/155A or S155A mutants. (a) BAD proteins lacking Ser155 are refractory to phosphorylation in cells. HEK293 cells were transfected with plasmids encoding the indicated BAD-GFP proteins and starved of serum (15 h) before labelling with 32 P-labelled orthophosphate (1 mCi/ml) for 6 h. For the last 30 min of this labelling period, the cells were stimulated with CPTcAMP (500 µM). The expressed proteins (confirmed by western blotting with anti-BAD antibody, top panel) were immunoprecipitated with anti-GFP antibody (Clontech), separated by SDS-PAGE, and the 32 P-labelled BAD-GFP proteins were detected by phosphorimaging. (b) Transfected HEK293 cells were labelled with 32 P-orthophosphate and stimulated with either CPTcAMP (500 µM) or 50 µM forskolin and 0.5 mM IBMX for the last 30 min. Cells expressing the S112/136A mutant (with intact Ser155) were pretreated with H89 (60 min, 30 µM) before stimulation with CPTcAMP or forskolin and IBMX. As a control, untransfected cultures were also treated with forskolin and IBMX, and subjected to the immunoprecipitation procedure as described above. H89 reduced phosphorylation of the S112/136A mutant by > 90%. of apoptosis observed in cells expressing wild-type BAD, or the S155A or S112/136A mutants was enhanced compared with that observed in the presence of serum for the respective protein, but there was no significant increase in apoptosis of cells expressing the triply mutated protein.
Although these data confirm the existence of serum factor(s) that induce the phosphorylation of Ser112 and/or Ser136, the data also reveal the importance of Ser155 as a regulatory site for the pro-apoptotic activity of BAD. These results do not, however, exclude the possibility that serum-activated kinases other than PKA might be responsible for the observed effects. In the presence of the pancaspase inhibitor Boc.Asp(O-methyl)CH 2 F (BAF), apoptosis induced by the triple mutant was completely suppressed (data not shown). Likewise, the extent of cleavage of PARP was greater in cells expressing BAD proteins bearing the S155A mutation and this cleavage was substantially blocked by BAF (Figure 3c ). Similar data were obtained using HeLa cells (data not shown). Thus, Ser155 can regulate the pro-apoptotic effect of BAD in live cells.
BAD is a pro-apoptotic member of the Bcl-2 family of proteins that exerts its death-promoting activity by heterodimerising with Bcl-XL or Bcl-2, death antagonists located mainly in the mitochondria [4] . In response to stimulation by survival factors, BAD has been shown to be phosphorylated on Ser112 (RSRHSpSYP) and Ser136 (RQRSTpSTP), upon which it dissociates from Bcl-XL/Bcl-2 and becomes sequestered by 14-3-3 proteins in the cytosol [5] . Although both serines lie within PKB consensus sequences (RXRXXS), only Ser136 appears to be phosphorylated by PKB [1] [2] [3] . Phosphorylation of Ser112 is mediated by PKA [6] , or by pp90RSK through a pathway dependent on the kinase MEK [7] [8] [9] . The p21-activated kinase 1 (PAK1) also phosphorylates BAD in vitro and in vivo on both Ser112 and Ser136 and inhibits the pro-apoptotic effects of BAD [10] . The existence of other sites in BAD that are phosphorylated by other kinases has also been suggested recently; for example, granulocyte macrophage colony stimulating factor (GMCSF) stimulates both cell survival and phosphorylation of BAD in the absence of detectable PKB activity [11, 12] . Moreover, Raf-1 targeted to mitochondria also phosphorylates BAD at sites other than Ser112 and Ser136 [13] [14] [15] . However, the methods used to reveal BAD phosphorylation in these studies preclude identification of the specific residue(s) involved. We have now found that Ser155 is an important PKA-dependent phosphorylation site in BAD. The general role of BAD phosphorylation in the maintenance of cell survival is still controversial and, moreover, the mechanism by which BAD is phosphorylated is more complicated than was previously thought. The identification of Ser155 as a site in BAD that is phosphorylated in vivo provides another mechanism by which BAD can integrate signals from upstream kinases. Although both Ser112 and Ser136 are nested within consensus binding motifs for 14-3-3 [16, 17] , the flanking sequences around Ser155 do not conform to a 14-3-3-binding motif. Ser155 of murine BAD is, however, located within the BH3 domain that has previously been shown to be crucial for the interaction of BAD with other Bcl-2 family members [18] . Thus, it is likely that phosphorylation of Ser155 is sufficient to induce a conformational change that enhances the dissociation of BAD from Bcl-2/Bcl-XL. In summary, we have identified Ser155 as the major PKAand serum-dependent phosphorylation site in BAD, and shown that its mutation enhances the pro-apoptotic function of BAD in living cells.
Materials and methods

Tissue culture, transfections and measurement of apoptosis
CHO-K1 cells were maintained in Ham F-12 medium (Gibco) containing 10% heat-inactivated fetal bovine serum. HEK293 cells were maintained in DMEM containing 10% fetal calf serum. For transfections, cells were grown overnight in 24-well plates washed three times in Optimem 1 (Gibco) and transfected with 0.1 pmol of the BAD-GFP expression vectors using 3 µl Lipofectamine (Gibco) per well. After 4 h, the cultures were switched to serum-containing medium for 15-18 h before exposure to the treatments indicated in the figure legends. BAD-GFP fusion proteins were detected on western blots using a polyclonal anti-BAD antibody, H168 (Santa Cruz). To determine the amount of apoptosis, cells were stained with Hoechst 33342 (2.5 µg/ml; Sigma) and the fraction of green cells (transfectants) displaying fragmented nuclei was calculated. PARP cleavage was measured using a monoclonal antibody as described [19] .
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Plasmid and DNA construction
To generate GST fusion constructs of wild-type BAD, and the S112A, S136A and S112/136A mutants, full-length murine bad cDNA sequences were amplified from the respective pSSFVBad recombinant vectors (kindly provided by Stanley Korsmeyer) by PCR and ligated into the pGEX4T-1 expression vector (Pharmacia) in frame with the carboxyl terminus of the GST coding sequence. The S155A mutants were generated by PCR site-directed mutagenesis (Quickchange, Stratagene) using the respective pGEX-Bad constructs as templates. GST fusion proteins were expressed in Escherichia coli strain BL21 and purified on glutathione-Sepharose beads (Pharmacia). To generate BAD-GFP fusion constructs, full-length sequences of murine Bad were subcloned from the respective pSSFVmBad recombinant vectors into the pEGFP-N1 mammalian expression vector (Clontech). The S155A constructs were generated by PCR site-directed mutagenesis using the respective pEGFP-mBad constructs as templates.
In vitro kinase assays
To measure BAD phosphorylation, respective GST-BAD fusion proteins (10-20 µg) were added to buffer containing 50 mM Tris-Cl (pH 7.4), 10 mM MgCl 2 , 1 mM DTT, 10 mM β-glycerophosphate, 50 µM ATP and 20 µCi [γ-32 P]ATP (Amersham). For PKA assays, 0.5 units of the catalytic subunit of PKA (P2645, Sigma) was added per reaction. In some cases, PKI (Bachem) was also added (5 µM). For PKB activity assays, a construct encoding the membrane-targeted form of PKB [20] was transfected into HeLa cells using Lipofectamine; 36 h post transfection, active PKB was immunoprecipitated from the detergent solubilised lysates using a polyclonal PKB antibody (a gift from Brian Hemmings) as described in [20] . Kinase reactions were conducted at 35°C for 30 min and terminated by the addition of SDS-PAGE loading buffer. The proteins were resolved on a SDS-polyacrylamide gel (7.5 or 10%) and 32 P-labelled fusion proteins were detected using a phosphorimager (Molecular Dynamics).
Metabolic labelling
HEK293 cells were transfected in 35 mm dishes as described above, washed once in serum-and phosphate-free RPMI and then incubated in phosphate-free RPMI (Gibco) buffered with sodium bicarbonate (2.2 g/l) containing 1 mCi 32 P-labelled orthophosphate (Amersham) for 6 h in a humidified atmosphere of 5% CO 2 /95% air. BAD-GFP was immunoprecipitated from detergent-solubilised lysates with an anti-GFP antibody (Clontech) and the immune complexes captured using protein A/G agarose. After washing in high salt (0.5 M NaCl) lysis buffer, the immunoprecipitates were eluted by boiling in gel loading buffer and fractionated on an SDS-polyacrylamide gel (10%); 32 P-labelled BAD-GFP was detected using a phosphorimager (Molecular Dynamics).
Supplementary material
Supplementary material including images of transfected cells is available at http://current-biology.com/supmat/supmatin.htm.
